Scotia Capital Inc. Ab Cellera Biologics Inc. Transaction History
Scotia Capital Inc.
- $17 Billion
- Q2 2024
A detailed history of Scotia Capital Inc. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Scotia Capital Inc. holds 15,069 shares of ABCL stock, worth $39,028. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,069
Previous 15,069
-0.0%
Holding current value
$39,028
Previous $68,000
35.29%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ABCL
# of Institutions
165Shares Held
119MCall Options Held
239KPut Options Held
200K-
Baker Bros. Advisors LP New York, NY27.5MShares$71.3 Million1.08% of portfolio
-
Baillie Gifford & CO21.9MShares$56.7 Million0.05% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$27.5 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA5.32MShares$13.8 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.6MShares$11.9 Million0.0% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $739M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...